Introduction
Epstein-Barr virus (EBV) is a human herpesvirus that causes infectious mononucleosis and is associated with the development of certain malignancies. The EBV genome is frequently present in African Burkitt's lymphomas, B-cell lymphomas of immunocompromised patients, nasopharyngeal carcinomas, and is present in some cases of Hodgkin's disease and gastric cancer (Kieff and Rickinson, 2001 ). In addition, there are preliminary reports suggesting that EBV can be found within a subset of breast cancers, prostate cancers, lung cancers, liver cancers, and colon cancers (Bonnet et al., 1999; Sugawara et al., 2000 , Grinstein et al., 2002 . Although EBV no doubt contributes to the development of many, if not all, of these tumors, the very presence of the EBV genome within these tumors nevertheless presents us with the unique opportunity to develop novel anticancer treatments directed against viral, rather than cellular, targets (Robertson et al., 1995; Ambinder et al., 1996; Guitierrez et al., 1996) . In this article, we will review a variety of different EBV-based therapies currently being developed for the treatment of EBVpositive cancers, with particular emphasis on novel strategies that induce the lytic form of EBV infection in tumor cells. Although we will focus on EBV-based therapies, similar approaches for treating other virusassociated tumors (such as Kaposi's sarcoma, which contains the closely related herpesvirus, KSHV) can easily be envisioned.
Potential EBV targets
Persistent expression of certain EBV-encoded gene products is likely required for the continued growth of many, if not all, EBV-associated lymphomas. Therefore, therapies designed to inhibit the expression of EBVencoded oncogenes, or to induce loss of the EBV episome, would no doubt be useful for treating at least some EBV-associated lymphomas. The use of EBVdependent promoters and replication origins to express toxic genes preferentially within EBV-positive tumor cells is also being explored. Other novel strategies currently under development involve the purposeful induction of the lytic form of EBV replication in tumor cells, thereby using the virus itself to kill tumor cells in conjunction with the prodrug, ganciclovir (GCV), which is converted into its cytotoxic form in lytically infected cells. Finally, since EBV-infected tumor cells express viral antigens, strategies based upon enhancement of the host immune response to viral proteins are also being actively pursued and have already proven promising for treatment of certain types of tumors. Below, we briefly review the EBV lifecycle before discussing different types of EBV-based approaches for treating cancer.
Latent EBV infection
Like all herpesviruses, EBV can establish either a latent or lytic infection in host cells. The vast majority of EBVinfected tumor cells contain one of the three types of latent EBV infection, and expression of the latent EBV gene products is sufficient for immortalization of B cells in vitro Kieff and Rickinson, 2001 ). In the latent forms of infection, the virus is replicated once per cell cycle as an episome using the viral oriP replication origin, the viral EBNA-1 protein, and the host cell DNA polymerase Kieff and Rickinson, 2001) . LMP-1 is considered to be the major EBV oncogene, although several additional latent viral proteins are also required for EBV immortalization of B cells in vitro Kieff and Rickinson, 2001) . Unfortunately, drugs that specifically inhibit the latent form of EBV infection are not currently available.
The role of EBV in causing malignancies is thought to vary according to different types of viral latency and associated histologic type. Burkitt's lymphomas (BL) that contain EBV represent type I latency, in which viral gene expression is limited to the EBNA-1 protein and untranslated viral transcripts ('EBERs'). Although activation of c-myc by chromosomal translocation is clearly the primary oncogenic event in BL, the loss of the EBV genome in certain type I EBV-positive BL lines is nevertheless associated with loss of tumorgenicity in SCID mice (Ruf et al., 1999) . Thus, type I EBV latency may also contribute to certain EBV-positive BL, although specific mechanisms have yet to be determined. At the other extreme, type III latency, typified by EBVtransformed lymphoblastoid B cell lines (LCLs) in vitro and EBV-positive diffuse immunoblastic lymphomas, in vivo, is associated with expression of all nine latencyassociated proteins, including EBNA-1 as well as a variety of different EBV proteins (in particular, LMP-1 and EBNA-2) required for EBV transformation of B cells Kieff and Rickinson, 2001) . Such tumors are thought to be highly dependent upon the continued expression of EBV-encoded oncogenes. Thus, targeting the viral episome as a whole, and targeting specific latent gene products, may both be effective as viral-directed treatments of EBV-associated tumors (Figure 1 ).
Targeting the EBV episome
Chronic, low-dose hydroxyurea treatment can induce loss of viral episomes in some BLs and LCLs, although the mechanism of loss is not yet clearly defined (Chodosh et al., 1998) . Two BLs, Akata and Mutu, showed a gradual loss of viral episomes during hydroxyurea treatment in vitro. Interestingly, the EBVnegative Akata derivatives had a significant decrease in in vitro growth, formation of colonies in soft agar, and generation of tumors in SCID mice in comparison to the EBV-positive parental lines, although the EBV-negative Mutu derivatives were not significantly different from the parental strain in these properties. Hydroxyurea treatment of two LCLs with episomal EBV also resulted in a decreased number of viral episomes as well as retardation or cessation of growth when compared to an LCL with chromosomally integrated viral DNA. On the basis of these findings, low-dose hydroxyurea was used to treat two patients with AIDS-related primary central nervous system lymphoma, which historically is associated with a median survival of 3 months. Both patients showed clinical improvement in the absence of CD4 þ T-cell reconstitution, and survived over 21 months (Slobod et al., 2000) . These reports, taken together, suggest that some EBV-positive tumors may be responsive to low-dose hydroxyurea with minimal toxicity, but that integration of viral DNA into the host chromosome or accumulated oncogenic mutations in a malignant lineage would be expected to limit efficacy. Larger, controlled trials will be needed to confirm the utility of this approach.
Another technique for episomal targeting is suggested by the observation that the cellular genome contains numerous sites for origin of replication complexes (ORCs) to regulate initiation of DNA synthesis, while EBV episomes are thought to contain only one major ORC. Replication of EBV episomes can be preferentially inhibited, compared to host DNA, by overexpressing geminin, a protein that interacts directly with Cdt1, and inhibits the recruitment of MCM proteins to the ORC (Dhar et al., 2001) . Thus, drugs that inhibit various aspects of ORC formation may eventually prove useful for inducing loss of the EBV episome in tumor cells. However, data regarding delivery, toxicity, and efficacy of this approach in animal models have yet to be developed.
Strategies that inhibit the EBV transforming proteins
Theoretically, inhibiting one or more of the EBV proteins known to be required for transformation of B cells in vitro (including LMP-1, EBNA-2, EBNA-3a and EBNA-3c) might reverse the oncogenic phenotype of at least some EBV-associated tumors. For example, antisense RNA directed against LMP-1 decreased the expression not only of LMP-1 in EBV-positive LCLs, Figure 1 Inhibition of transformation phenotype. Therapies that induce loss of the EBV episome (above), or which inhibit virally encoded oncogenes such as LMP-1 (below), are depicted but also cellular proteins induced by LMP-1, such as the antiapoptotic proteins Bcl-2 (Kenney et al., 1998a) . Furthermore, LMP-1-antisense RNA resulted in decreased LCL proliferation, increased apoptosis, and increased sensitivity to the cytotoxic drug etoposide (Kenney et al., 1998a) . Antisense RNA delivery in vivo has been studied using various modified oligonucleotide moieties and liposomal formulations, but the ability to deliver antisense RNA therapeutically will require further studies characterizing toxicity and efficacy (Putnam, 1996) . More recently, highly effective selective gene inhibition has been achieved with small interfering RNA (RNAi) technology, in which the expression of short (15-20 bp) double-stranded RNA sequences homologous to the gene of interest results in degradation of the target mRNA. This approach has been used successfully to modulate viral expression in vitro of HIV (Coburn and Cullen, 2002; Lee et al., 2002; Novina et al., 2002) , papillomavirus (Jiang and Milner, 2002) , and poliovirus (Gitlin et al., 2002) model systems. A similar approach using RNAi technology would likely be effective for inhibiting EBV latent gene expression in vitro, but clinical use will require the development of efficient delivery methods in vivo to tumor cells.
Viral transforming protein
Downstream effects of LMP-1 are mediated in part through activation of nuclear factor kappa-B (NF-kB) , and inhibition of NF-kB function using an inducible dominant repressor IKKB has been shown to result in spontaneous apoptosis of LCLs (Cahir-McFarland et al., 2000) . Similarly, aspirin has been shown to inhibit LMP-1 activation of matrix metalloproteinase-9 (MMP-9), a protein important for tumor invasion and metastasis, and this effect is at least partially mediated through an NF-kB-dependent mechanism (Murono et al., 2000) . However, as NF-kB plays a critical role in numerous cellular functions, tightly restricted expression of NF-kB inhibitors may be needed before in vivo applications can progress.
EBV-dependent expression of cellular toxins
Since all EBV-associated malignancies express EBNA-1, several groups have developed vectors that express toxins under the direction of the oriP enhancer element, which is activated by EBNA-1 binding (Reisman et al., 1985) (Figure 2 ). Transfection of an oriP-cytosine deaminase vector has been shown in vitro to sensitize EBV-positive, but not EBV-negative, cell lines to 5-fluorocytosine (Kenney et al., 1998b) , and oriP-based constructs have been developed that express HSV-TK (which converts the prodrug, GCV, into its cytotoxic form) in an EBNA-1-dependent manner (Hirai et al., 1997) . Recombinant adenoviral (rAd) vectors that express reporter genes or the p53 tumor suppressor gene under control of the oriP enhancer have 1000-fold more gene expression in EBV-positive, versus EBVnegative, cell lines . In addition, oriPbased episomal vectors that require the EBNA-1 protein in trans for replication have been used to preferentially express, and retain, cellular toxins in EBV-positive cells (Westphal et al., 2000b) . The EBNA-2 viral gene product is also a transcriptional activator, and an EBNA-2-responsive element positioned upstream of thymidine kinase sensitizes EBV-positive lymphomas to GCV killing (Franken et al., 1996) . Although potentially promising, each of the above strategies would require improvement of the currently available gene delivery methods before wide clinical applicability would be anticipated.
Induction of lytic EBV infection
Theoretically, the purposeful induction of the lytic form of EBV infection in tumor cells could be used to treat these malignancies (Figure 3 ). The switch from the latent to lytic form of EBV infection is mediated by the two viral immediate-early proteins, BZLF1 and BRLF1. The BZLF1 and BRLF1 gene products encode transcription factors that together activate the entire lytic viral cascade of gene expression, ultimately resulting in the production of infectious viral particles (Countryman and Miller, 1985; Chevallier-Greco et al., 1986; Takada et al., 1986; Hardwick et al., 1998; Ragoczy et al., 1998; Rooney et al., 1988; Farrell et al., 1989; Rooney et al., 1989; Chang et al., 1990; Zalani et al., 1996; Feederle et al., 2000) . Since the BZLF1 and BRLF1 proteins each activate one another's promoters, overexpression of either protein in latently infected cells is usually sufficient to activate the lytic form of EBV infection. In cells containing the latent form of EBV infection, the two promoters (Zp and Rp) that control transcription of the BZLF1 and BRLF1 gene products are inactive. Transcription of the two EBV immediate-early genes in vitro is induced by stimuli that activate B cells, such as antigen receptor engagement (Takada, 1984) , calcium ionophores (Faggioni et al., 1986) , and phorbol esters (Zur Hausen et al., 1978) . In vivo, it is thus likely EBV tends to stay in the latent form of infection in quiescent B cells, and switches to the lytic form of infection in highly activated B cells. The latent EBV gene product, LMP-2, is thought to play an important role in helping to maintain viral latency in B cells by suppressing the signal transduction cascades which are normally induced by B-cell activation (Miller et al., 1995) .
Although a number of cellular factors have been shown to bind to the BZLF1 (Zp) and BRLF1 (Rp) promoters, relatively few of these transcription factors induce activation of the promoters (Figure 4 ). In the case of the BZLF1 promoter (Zp), full activation Toxin expression specific to EBV-containing cells Figure 2 Latent viral promoters that require EBV-encoded gene products in trans, or the oriP replication origin that requires EBNA-1 in trans, can be used to produce cellular toxins specifically in EBV-positive cells requires both a 'ZII' motif (which binds CREB, ATF1, and a c-jun/ATF-2 heterodimer) and several different 'ZI' binding sites, which bind MEF2D as well as Sp1 and Sp3 (Flemington and Speck, 1990; Daibata et al., 1994; Speck et al., 1997; Wang et al., 1997; Adamson et al., 2000; Binne et al., 2002; Bryant and Farrell, 2002; Gruffat et al., 2002) . Calcium-induced activation of MEF2D (mediated by calcineurin) and CREB (mediated by CaMKIV/GR) appears to be important for BZLF1 promoter activation following ligation of the B-cell receptor Liu et al., 1997) . The inducing effect of phorbol esters is mediated through protein kinase C (PKC) (Davies et al., 1991) , and also primarily requires the ZI and ZII binding motifs in the BZLF1 promoter , although the intermediary factors are not well defined. However, PKC activation is not required for induction of lytic EBV by certain stimuli (Gradoville et al., 2002) . Activation of the BRLF1 (Rp) promoter requires EGR-1 and Sp1 binding sites (Zalani et al., 1992 (Zalani et al., , 1995 . Both IE promoters are negatively regulated by binding sites for the cellular YY-1 transcription factor (Montalvo et al., 1995; Zalani et al., 1997) , and BZLF1 transcription is also inhibited by binding of the zincfinger protein, ZEB (Kraus et al., 2001) , as well.
Epigenetic factors also play an important role in regulating the state of EBV infection in host cells. In cells containing tightly latent EBV infection, the viral IE promoter DNA is often methylated (Falk and Ernberg, 1999) , and the chromatin surrounding the IE promoters is in the unacetylated (inactive) form (Chang and Liu, 2000; Jenkins et al., 2000; Gruffat et al., 2002) . Treatment of certain Burkitt's cell lines in vitro with agents that induce histone acetylation (Luka et al., 1979; Westphal et al., 2000a) or reverse DNA methylation (Ben-Sasson and Klein, 1981 ) is sufficient to induce the lytic form of EBV infection in a subset of cells, although such agents are generally not very effective in inducing lytic EBV infection in EBV-immortalized lymphoblastoid cell lines (Westphal et al., 2000a) .
Inducing lytic EBV infection in tumor cells: two potential strategies
Theoretically, there are at least two different potential methods for inducing the lytic form of EBV infection in tumor cells. One approach would be to express EBV IE gene product in tumor cells, under the control of a strong heterologous promoter, using gene delivery methods. This approach, while having the obvious advantage of bypassing the tightly repressed promoters which normally drive BZLF1 and BRLF1 transcription, is hampered by the same concerns of inefficient delivery and nonspecific toxicity that currently plague all gene delivery strategies for treating cancer. A second approach would be to develop methods (preferably Figure 4 Upregulating pathways of EBV lytic reactivation. Induction of lytic EBV can occur as a result of BCR signal transduction or cellular stress. Calcium-dependent mechanisms, as well as the PKC, p38 and JNK stress MAP kinases, and PI3-K pathway, appear to be involved. A simplified model indicating positive regulatory elements in the BZLF1 (Zp) and BRLF1 (Rp) promoters is presented (adapted from Speck et al., 1997; Campbell, 1999) through delivery of drugs or other small molecules) for inducing expression of the EBV immediate-early genes from the endogenous viral genome in tumor cells. The success of this second approach may ultimately require a more thorough understanding of the viral and cellular factors that activate, as well as repress, EBV IE gene transcription. However, progress is being made, as discussed below. An advantage of lytic induction strategies may be the relatively selective destruction of tumor cells, since the EBV genome is normally found in only a very few (approximately one in a million) normal B cells, but is present in virtually all tumor cells in EBVpositive lymphomas . Also, induction of lytic EBV infection can be combined with the cytotoxic drug, ganciclovir, which is converted to its active form by the lytic form of EBV infection, to optimize tumor cell killing. In contrast to the strategies that attempt to inhibit latent EBV replication or latent EBV gene expression, lytic induction strategies do not require that the continued presence of EBV is important for tumor growth.
Gene delivery of EBV IE proteins to tumor cells
Transfection of EBV-positive tumors cells with a BZLF1 expression vector induces not only the lytic form of EBV infection, but tumor cell killing . Adenovirus vectors expressing either EBV IE protein (BZLF1 or BRLF1) have been used to infect both EBV-positive Burkitt's lymphomas and nasopharyngeal carcinomas grown in nude mice, and in each case have been shown to induce the lytic form of EBV infection (Westphal et al., 1999; Feng et al., 2002b) . In addition, infection of nasopharyngeal carcinomas (grown in nude mice) with either BZLF1 or BRLF1 adenovirus vectors inhibited tumor growth in comparison to a control adenovirus vector (Feng et al., 2002b) . These studies provide 'proof of concept' for the rational use of lytic EBV induction as an antitumor strategy. Clearly, a number of hurdles must be overcome before gene delivery methods for inducing lytic EBV infection in tumors will be widely useful in patients, and it may be difficult with any currently available gene delivery method to infect enough tumor cells to have clinically useful outcomes. Assuming that efficient gene delivery methods can be developed, nonspecific toxicity because of high-level expression of the IE proteins in EBVnegative cells may be an issue. While there is evidence that high-level expression of the BZLF1 protein induces considerably more toxicity in EBV-positive cells than in EBV-negative cells, high-level expression of the BRLF1 protein is toxic even in EBV-negative cells (Feng et al., 2002b) . Given the known ability of BZLF1 to inhibit cell-cycle progression in some cell types (Cayrol and Flemington, 1996) , vectors that use an EBV-dependent promoter to drive BZLF1 transcription may be required to avoid all nonspecific toxicity. Although there is a theoretical concern that release of infectious viral particles could result in the infection and transformation of new host cells, in reality EBV-associated tumorigenesis appears to be a multistep process such that EBVinfected cells only rarely become transformed, and EBV reactivation is thought to be largely asymptomatic. In any event, infection of new host cells could be easily prevented with the concomitant administration of an antiviral drug.
Activation of lytic EBV transcription by modification of chromatin or DNA methylation
There is considerable interest in developing drugs or other small molecules capable of activating the BZLF1 and/or BRLF1 IE promoters within the endogenous (latent) viral genome of EBV-positive tumors. In cells containing latent forms of EBV infection, both demethylating agents, and agents that induce histone acetylation, can activate the lytic form of EBV infection in certain cell lines. Thus, demethylating agents, such as 5-azacytidine, or agents that induce histone acetylation, such as butyrates, might likewise accomplish this task in patient tumors (Mentzer et al., 1998) . The results of a small nonrandomized trial using the combination of arginine butyrate and ganciclovir to treat patients with EBV-associated lymphomas appear promising (Mentzer et al., 2001) . However, it remains to be shown in patient tumor samples whether the treatment effect of butyrate is actually related to the induction of lytic EBV, versus EBV-independent effects on cellular gene expression and cell-cycle progression. Although both butyrate and 5-azacytidine induce lytic EBV infection in certain Burkitt's cell lines in vitro, we have not been able to show that treatment of mice with either 5-azacytidine, or butyrate, effectively induces the lytic form of EBV infection in tumors derived from lymphoblastoid cell lines (Westphal et al., 2000a; and unpublished data) .
Activation of BZLF1 and BRLF1 transcription from the endogenous EBV genome in tumor cells using conventional cytotoxic therapies Although a specific, nontoxic strategy for efficiently inducing lytic EBV gene transcription in tumor cells has yet to be developed, almost all agents used to activate lytic EBV infection in vitro are also capable of inducing cellular apoptosis (Inman et al., 2001) . It was recently shown that a number of the treatments that are already routinely used in patients to treat EBV-positive tumors, including gamma irradiation and various types of chemotherapy, have the additional property of inducing lytic viral gene expression in a portion (up to 25%) of the tumor cells (Feng et al., 2002a; Westphal et al., 2000a) . The ability of chemotherapy to induce lytic EBV reactivation appears to require the simultaneous engagement of several different signal transduction pathways, including cellular stress MAP kinase p38, PI3 kinase, PKC delta, and ERK 1/2, but not cellular apoptosis per se (Feng et al., 2002a, and unpublished data) . Interestingly, activation of these same cellular signal transduction pathways is also required for lytic EBV infection following engagement of the B-cell receptor (Adamson et al., 2000; Darr et al., 2001; Bryant and Farrell, 2002) , suggesting that similar transcription factors may be involved. In addition, BRLF1-induced activation of the BZLF1 promoter requires the stress MAP kinases, p38 and c-jun Nterminal kinase, as well as PI3 kinase (Adamson et al., 2000; Darr et al., 2001) . Activation of the BZLF1 promoter through the stress MAP kinases is likely mediated through phosphorylation of the ATF-2/c-jun heterodimer that binds to the ZII (CRE) site (vanDam et al., 1995; Adamson et al., 2000) . In addition, p38 has been shown to phosphorylate, and activate, some members of the MEF2 family (Zhao et al., 1999) , and MEF2 binding sites in the BZLF1 promoter are also essential for BZLF1 transcriptional activation following various physiologic stimuli . Likewise, PI3 kinase has been shown to increase the transcriptional activity of at least some MEF2 family members (Tamir and Bengal, 2000) , and can activate promoters through CRE sites (Wang et al., 1999) . Finally, both gamma irradiation and chemotherapy induce activation of the cellular immediate-early protein EGR-1 (Datta et al., 1993; Lim et al., 1998) , at least partially through a p38 kinase-dependent mechanism, and EGR-1 has been shown to bind and activate the BRLF1 promoter (Zalani et al., 1995) . Thus, although not previously recognized, conventional therapy of EBV-positive tumors in vivo is associated with the induction of lytic EBV infection in at least a portion of tumor cells, and this effect is likely because of the ability of chemotherapy to activate many of the same cellular signal transduction pathways that normally serve to activate BZLF1 and BRLF1 transcription following ligation of the B-cell receptor. EBV thus appears to be capable of recognizing a host cell environment indicative of cellular stress, and uses these signals to convert to the lytic form of infection and escape a potentially dying host cell.
Ganciclovir enhances the antitumor effect of chemotherapy and gamma irradiation in EBV-positive tumor cells
The discovery that conventional treatment for EBVpositive tumors induces a portion of the tumor cells to convert to the lytic form of viral infection suggested that the antiviral drug, ganciclovir, might augment the therapeutic effect of chemotherapy (or irradiation) for EBV-positive tumors. Tumor cells containing the lytic (but not latent) type of EBV infection express virally encoded kinases (BGLF4 and the viral thymidine kinase) that induce phosphorylation of the prodrug, GCV, converting it to its active cytotoxic form (Moore et al., 2001) . Phosphorylated GCV inhibits not only the virally encoded DNA polymerase, but also inhibits the host cell DNA polymerase and is thus cytotoxic (Tiberghien, 1994; Conners, 1995) . Furthermore, phosphorylated GCV can be transferred into nearby cells, thus inducing 'bystander' killing (Freeman et al., 1993; Chen et al., 1995; Conners, 1995) . In addition, there is evidence that phosphorylated GCV can synergistically kill cells when combined with either certain types of chemotherapy, or irradiation (Kim et al., 1997; Aghi et al., 1998; Wildner et al., 1999) .
Since EBV-positive tumor cells are primarily infected with the latent forms of EBV infection, GCV by itself is not useful for treating EBV-positive tumors. However, given that chemotherapy and irradiation both induce the lytic form of EBV infection in a portion of tumor cells, the combination of conventional chemotherapy or irradiation with GCV might be more effective than chemotherapy or irradiation alone for treating EBVpositive tumors. In tissue culture and animal models for EBV-positive tumors, this turns out to be the case. GCV rather dramatically enhances the treatment effect of both chemotherapy and irradiation in an EBV-dependent manner, while at the same time preventing the release of infectious EBV virions (Westphal et al., 2000a; Feng et al., 2002a) . These animal results suggest that a relatively simple strategy, adding GCV to conventional chemotherapy or irradiation, might likewise be useful for treatment of patient tumors. Nevertheless, it will be important to document that clinically relevant doses of chemotherapy and irradiation actually activate lytic EBV gene expression in patient tumors, and to define the chemotherapy agents most effective in this regard for each tumor type.
Enhancing the immune response to viral proteins
In the last decade, a growing literature has demonstrated that some EBV-associated malignancies are amenable to immune reconstitution with ex vivoexpanded EBV-specific cytotoxic T lymphocytes (EBV-CTL) ( Figure 5 ). Not surprisingly, EBV-CTL therapy appears to be most effective for treating those tumors (i.e. post-transplant lymphomas) where the lack of a normal T-cell response to EBV-infected cells is thought to play a key role in the development of the tumor. EBNA-2, EBNA-3a, -3b, and -3c, and to a lesser extent LMP-2, contain the immunodominant epitopes for latent EBV proteins in normal CTL responses (Murray et al., 1992; Chapman et al., 2001) . Post-transplant-type lymphomas, which typically contain type III latency gene expression, express the full complement of latent virus protein immunodominant epitopes for the host CTL response. EBV-CTL therapy has been shown to be effective when administered prophylactically post-transplant, and is also effective in some cases of established PTLD without significant toxicity . However, a patient was recently described who died of advancing disease despite adoptive transfer of EBV-CTL because of a deletion mutation in EBNA-3B, the dominant CTL epitope, allowing escape from immune surveillance .
In contrast, viral gene expression in tumors with type II latency, as seen in nasopharyngeal carcinoma and EBV-associated HD, is restricted to EBNA-1, LMP-1, LMP-2, and BARF0 (which is transcribed but possibly not translated). CTLs isolated from HD patients and examined in tumor sections are predominantly directed against EBNA 2 and EBNA3 epitopes (Chapman et al., 2001) . Clinical trials of EBV-CTL therapy for such tumors are ongoing Chua et al., 2001) . CTL responses to LMP-1/2 epitopes can be generated in vitro (Meij et al., 2002) , and several groups have addressed in vitro the presumed requirement to enhance CTL response to LMP-2 and/or LMP-1 (Gahn et al., 2001; Su et al., 2001) . Nevertheless, the fact that such tumors can develop in hosts with apparently intact CTL function suggests that tumor paracrine effects, such as secreted TGF-b and IL-10, may limit the function of EBV-specific CTLs. Attempts are being made to modify EBV-CTLs ex vivo to resist such local tumor immunosuppressive effects (Bollard et al., 2002) . Increased expression of the highly immunogenic latent EBV proteins (such as EBNA-3) in tumors with type I or II latency could possibly be accomplished using demethylating agents (Robertson et al., 1995) . In addition, since much of the normal host CTL response is directed against the viral lytic proteins, the combination of lytic induction strategies with EBV-CTL therapy may be more effective than either approach alone (Figure 3 ).
Summary
The consistent presence of certain viruses such as EBV in particular tumor types offers the potential for the development of highly specific, viral-targeted therapies. As our understanding of EBV pathogenesis, viral gene regulation, and cellular transformation continues to grow, additional EBV-based targets are likely to be identified. Given the ever-growing number of tumor types associated with EBV infection, the development and testing of an EBV vaccine may be warranted, in an attempt to reduce the number of EBV-associated cancers.
